Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108906
Filing Date
2025-08-14
Accepted
2025-08-14 16:19:56
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20250630.htm   iXBRL 10-Q 2593257
2 EX-10.1 pyxs-ex10_1.htm EX-10.1 181990
3 EX-31.1 pyxs-ex31_1.htm EX-31.1 16366
4 EX-31.2 pyxs-ex31_2.htm EX-31.2 16440
5 EX-32.1 pyxs-ex32_1.htm EX-32.1 9933
6 EX-32.2 pyxs-ex32_2.htm EX-32.2 9292
7 GRAPHIC img33345613_0.jpg GRAPHIC 1147976
  Complete submission text file 0000950170-25-108906.txt   12374515

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20250630.xsd EX-101.SCH 1326120
68 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20250630_htm.xml XML 1482405
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 251219552
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)